MRK · News · 20260826N

Product / Drug Pipeline Progress

Merck & Co., Inc. · 2026-08-26 · Importance 33 · Surprise 42

Merck and Moderna announced positive Phase 3 results for their personalized, mRNA-based cancer vaccine. The vaccine is described as a personalized cancer therapy and is contributing to renewed investor confidence in Merck’s pipeline. The development may help diversify Merck’s portfolio and mitigate the expected impact of Keytruda’s patent expiration in 2028.

Key facts

• Merck's stock reached a new 52-week high driven in part by positive clinical trial data for its personalized cancer therapy with Moderna. source
• Merck and Moderna announced positive Phase 3 results for their mRNA-based cancer vaccine. source